CClinicalTrials.gg
CompletedNCT01591408Updated Dec 20, 2016Results posted

EEG Biofeedback Therapy as an Adjunct Treatment for PTSD

An interventional study of EEG biofeedback in PTSD, Anxiety and Trauma, sponsored by United States Naval Medical Center, San Diego. Completed at 1 site in United States. Open to male participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2016-12-20.

Sponsored by United States Naval Medical Center, San Diego · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Study summary

The proposed study, "Placebo-controlled study of EEG biofeedback therapy as an adjunct treatment for PTSD, evaluating symptoms and EEG dynamics", will investigate the brain dynamics associated with PTSD symptom reduction associated with EEG biofeedback therapy or sham EEG biofeedback in addition to treatment as usual at the Naval Medical Center, San Diego (NMCSD) OASIS program.

EEG biofeedback treatment protocols for PTSD and other disorders have been developed and honed by private practice clinicians over the past 25 years, during which EEG biofeedback has become an increasingly popular adjunct therapy.

The reported success of EEG biofeedback as a non-drug intervention with lasting efficacy warrants a clinical study investigating not only symptom reduction, but also the underlying neurobiological mechanism. To this end, we propose a study using high density EEG recordings before and after treatment for PTSD symptoms to determine which brain activities correlate with reported symptom changes.

The proposed study could expand treatment alternatives for servicemen with PTSD. If EEG biofeedback is shown to improve symptom reduction over the placebo controlled condition, it would offer a non-pharmacological intervention that would avoid undesirable side effects, and accelerate recovery compared with the current standard of care.

Read the detailed description

EEG biofeedback is an emerging alternative approach to treating PTSD, for which there is still insufficient evidence to assume unequivocal clinical utility. However, a 1991 report showed PTSD symptom reduction in 14 subjects receiving EEG biofeedback, as compared to 13 subjects receiving traditional treatment (Peniston, 1991), and a recent case study of 2 PTSD patients receiving EEG biofeedback therapy also showed reduce symptom severity using a newer protocol and device (Othmer, 2009). Another recent study focused on the anxiety symptoms of PTSD and showed that EEG biofeedback significantly reduced anxiety compared to subjects not receiving treatment (Walker, 2009).

EEG biofeedback has also been explored as a treatment for non-PTSD related anxiety disorders, with results showing significant changes in reported anxiety correlated with increased or decreased alpha-frequency (\~8-12 Hz) power (Hardt, 1978). Similarly, alpha-frequency EEG biofeedback has been shown to reduce anxiety and to reduce heart rate reactivity to a stressor after 8 sessions of EEG biofeedback training (Rice, 1993). While EEG biofeedback has been shown to significantly change EEG power dynamics (Egner, 2004), it is still unclear if and how EEG biofeedback can effect long-term and complex changes in cognitive and/or emotional functioning.

Some attention has been given to other types of biofeedback for the treatment for PTSD, such as heart rate variability (HRV) biofeedback, which may be relevant in understanding the background of biofeedback with respect to PTSD treatment. While one study reported no difference in symptom reduction between treatment as usual and treatment as usual plus HRV biofeedback (Lande, 2010), a handful of other studies have reported significant associations between HRV changes and PTSD symptoms. Specifically, increased HRV was significantly correlated with PTSD symptom reduction, which was more effective with respiratory sinus arrhythmia (RSA) (which affects HRV) biofeedback than with progressive muscle relaxation (Zucker, 2009). Furthermore, combat-related PTSD subjects showed lower resting HRV than controls, but training with HRV biofeedback increased PTSD subjects' HRV and simultaneously decreased their PTSD symptoms (Tan, 2011). Finally, a quantitative EEG study showed that an acute session of RSA biofeedback was associated with an increase in alpha-band power and reduced higher frequency beta-band power, suggesting a neural impact of RSA training and HRV regulation (Sherlin, 2010).

Summary The proposed study of EEG biofeedback at the OASIS program will not only address the clinical efficacy, but also the brain activations associated with specific symptoms of PTSD through collection of high-density EEG data before and after EEG biofeedback treatment. These data will help elucidate the neural correlates of PTSD symptom expression as well as address the potential efficacy of EEG biofeedback therapy as an adjunct treatment for PTSD-like symptoms.

02

Conditions studied

  • PTSD
  • Anxiety
  • Trauma
  • Sleep Disorders

Browse trials for

Keywords

  • EEG biofeedback
  • neurofeedback
  • therapy
  • adjunct
03

In context

Sleep Wake Disorders

788 studies on the registry are indexed under Sleep Wake Disorders; 186 are open to participants now.

This study's enrollment of 68 is close to the median of 62 across 548 interventional studies indexed under Sleep Wake Disorders.

Browse Sleep Wake Disorders studies →

Lead sponsor

United States Naval Medical Center, San Diego is the lead sponsor of 63 studies on the registry; 6 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Male,
  • active military,
  • participating in PTSD program at NMCSD

Exclusion criteria

Exclusion Criteria:

  • Seizure disorder.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    EEG biofeedback

    Subjects will receive EEG biofeedback according to their own brain rhythms

    Device: EEG biofeedback

  • Sham comparator
    sham EEG biofeedback

    Subjects will receive feedback according to someone else's brain rhythms collected during a different session.

    Device: EEG biofeedback

Interventions

  • DeviceEEG biofeedback

    EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.

    Also known as: EEG info device

06

What researchers measure

Primary outcomes

  1. Improved Symptom Ratings

    Will test whether subjects receiving real EEG biofeedback report decreased anxiety and irritability relative to subjects receiving sham biofeedback. The scale for each rating was a 0-10, with 0 meaning "not at all" and 10 being "extremely" anxious/irritable.

    Time frame: 4 weeks

07

Results

Posted Dec 20, 2016

Participant flow

Participant flow — Overall Study
MilestoneEEG BiofeedbackSham EEG Biofeedback
Started3632
Completed2424
Not completed128

Outcome measures

PrimaryImproved Symptom Ratings

Will test whether subjects receiving real EEG biofeedback report decreased anxiety and irritability relative to subjects receiving sham biofeedback. The scale for each rating was a 0-10, with 0 meaning "not at all" and 10 being "extremely" anxious/irritable.

Time frame:
4 weeks
Reported as:
Mean · Rating on scale
Improved Symptom Ratings
Rating on scaleEEG BiofeedbackSham EEG Biofeedback
Irritability-2.62 ± 2.40-1.62 ± 2.23
Anxiety-2.25 ± 2.22-1.21 ± 2.23

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EEG Biofeedback———
Sham EEG Biofeedback———

Baseline characteristics

Age, Continuous
Age, Continuous(years)EEG BiofeedbackSham EEG BiofeedbackTotal
Mean30.4 ± 5.229.4 ± 5.629.9 ± 5.4
Gender
Gender(Participants)EEG BiofeedbackSham EEG BiofeedbackTotal
Female235
Male222143
Region of Enrollment
Region of Enrollment(participants)EEG BiofeedbackSham EEG BiofeedbackTotal
United States242448
08

Study locations

1 site
  • OASIS PTSD program
    San Diego, California, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01591408
Lead sponsor
United States Naval Medical Center, San Diego
Collaborators
Naval Health Research Center
Responsible party
Sponsor
First posted
May 4, 2012
Start date
May 2012
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Dec 20, 2016
Last update
Dec 20, 2016

Study contacts

Julie A Onton, PhD
principal investigator · Naval Health Research Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion